- Home
- UCAR vs PHGE Comparison
UCAR vs PHGE Comparison
Compare UCAR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- PHGE
- Stock Information
- Founded
- UCAR 2013
- PHGE 2015
- Country
- UCAR China
- PHGE Israel
- Employees
- UCAR 80
- PHGE N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- UCAR Consumer Discretionary
- PHGE Health Care
- Exchange
- UCAR Nasdaq
- PHGE Nasdaq
- Market Cap
- UCAR 13.3M
- PHGE 14.6M
- IPO Year
- UCAR 2023
- PHGE N/A
- Fundamental
- Price
- UCAR $3.15
- PHGE $0.48
- Analyst Decision
- UCAR
- PHGE Strong Buy
- Analyst Count
- UCAR 0
- PHGE 1
- Target Price
- UCAR N/A
- PHGE $15.00
- AVG Volume (30 Days)
- UCAR 19.1K
- PHGE 95.1K
- Earning Date
- UCAR 06-17-2025
- PHGE 05-15-2025
- Dividend Yield
- UCAR N/A
- PHGE N/A
- EPS Growth
- UCAR N/A
- PHGE N/A
- EPS
- UCAR N/A
- PHGE N/A
- Revenue
- UCAR $6,067,871.00
- PHGE N/A
- Revenue This Year
- UCAR N/A
- PHGE N/A
- Revenue Next Year
- UCAR N/A
- PHGE N/A
- P/E Ratio
- UCAR N/A
- PHGE N/A
- Revenue Growth
- UCAR 124.09
- PHGE N/A
- 52 Week Low
- UCAR $2.30
- PHGE $0.45
- 52 Week High
- UCAR $9.43
- PHGE $4.38
- Technical
- Relative Strength Index (RSI)
- UCAR 59.14
- PHGE 37.53
- Support Level
- UCAR $3.05
- PHGE $0.47
- Resistance Level
- UCAR $3.41
- PHGE $0.57
- Average True Range (ATR)
- UCAR 0.22
- PHGE 0.04
- MACD
- UCAR 0.01
- PHGE -0.00
- Stochastic Oscillator
- UCAR 69.23
- PHGE 23.93
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).